Startups channel feed – Endpoints News

Startups channel feed

Venrock takes the wrap off its first microbiome startup, armed with $50M, a CEO from 23andMe and two founders from Stanford

5 years ago

The latest Jennifer Doudna startup launches with a Biogen partnership and eyes on big targets few CRISPR companies have chased

5 years ago

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

5 years ago

A pharma exec gets $100M to chase a cancer-fighting idea uncovered in a 2017 Novartis study

5 years ago

With a $4M federal grant, Lumen jumps into the Covid-19 treatment race

5 years ago

Flagship's next big technological bet? The cloud

5 years ago

With $29M in Series A, Boehringer-backed Libra looks to tackle neurodegeneration through cellular cleaning

5 years ago

Immetas Therapeutics nabs $11M Series A to narrow their bispecific work targeting inflammation in age-related diseases

5 years ago

Can a magnetic cell therapy replace corneal transplantation? As eight-year journey leads to the clinic, two brothers unveil bold vision

5 years ago

Lava breaks prolonged silence with an $83M Series C and two I/O programs set for the clinic

5 years ago

Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell

5 years ago

Arie Belldegrun and David Chang godfather the $110M launch of a new cell therapy player. And this one is also thinking big

5 years ago

Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibody

5 years ago

FL56+FL57= infinite possibilities? Flagship's hybrid startup takes machine learning in drug discovery to the next level — and Covid-19 offers a quick test

5 years ago

New targeted therapy approaches win Rain Therapeutics $63M — designed to beat a quick path to approval

5 years ago

A pair of Bay Area biotech upstarts with deep pockets and a shared interest in curative cancer drugs join R&D forces

5 years ago

Driving to the $278M mark on raises, a legendary R&D expert sets his sights on another pivotal goal line

5 years ago

'We want to be everywhere.' Mission Bio raises $70M behind resistance-hunting sequencing platform

5 years ago

Perceptive births its first in-house startup — and it's a China play

5 years ago

RA Capital-backed Aerovate launches with $72.6M to treat PAH with a repurposed cancer med

5 years ago

Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform

5 years ago

Less than 3 months after launch, the AveXis crew’s Taysha raises $95M Series B. Is an IPO next?

5 years ago

Versant debuts Ridgeline's startup #4, armed with $30M and alternative TCR cell therapies for solid tumors

5 years ago

IgGenix emerges from stealth with $10 million Series A hoping to re-engineer allergic cascade

5 years ago

First page Previous page 51 52 535455 56 57 Next page Last page